CaseTrail

Mutual Pharmaceutical Company, Inc. v. Karen L. Bartlett

570 U.S. 472 · Decided June 24, 2013 · Supreme Court of the United States

Record summary. This page is generated from the Supreme Court Database’s coded data about the case. It describes who decided what, not the Court’s reasoning. Read the opinion itself before relying on it. Not legal advice.

At a glance

Mutual Pharmaceutical Company, Inc. v. Karen L. Bartlett was decided on June 24, 2013 by a vote of 5–4. The Court reversed the lower court's decision. Justice Samuel A. Alito Jr. wrote the opinion of the Court. SCDB classifies its main issue as “Federal preemption of state legislation or regulation” in the Federalism area.

Read the opinion

Case details

Citations
570 U.S. 472 · 133 S. Ct. 2466 · 186 L. Ed. 2d 607 · 2013 U.S. LEXIS 4702
Docket number
12-142
Decided
June 24, 2013
Argued
March 19, 2013
Court era
Roberts Court
Decision type
Opinion of the Court (orally argued)
Disposition
Reversed
Outcome for petitioner
The petitioning party received a favorable disposition
Vote
5–4
Majority opinion
Samuel A. Alito Jr.
Opinion assigned by
John G. Roberts Jr.
How the case arrived
Certiorari
Issue area
Federalism
Legal provision
Federal Food, Drug, and Cosmetic Act
Type of law
Federal statute
Decision direction (SCDB)
Liberal what this means

How the Justices voted

Full case caption

Mutual Pharmaceutical Company, Inc., Petitioner v. Karen L. Bartlett

SCDB identifiers: case 2012-069, docket 2012-069-01.

Other cases on “Federal preemption of state legislation or regulation”

See all

Cases on the same legal provision: Federal Food, Drug, and Cosmetic Act

Same Term, same area (Federalism)

See all

Source: Supreme Court Database, 2026 Release 01 (data file dated September 8, 2026). Imported into CaseTrail November 5, 2026. Coverage: decisions from the 1946 through 2025 Terms. Methodology · Report an error